Akademik Veri Yönetim Sistemi
Türk Kardiyoloji Derneǧi arşivi : Türk Kardiyoloji Derneǧinin yayin organidir, cilt.37 Suppl 7, ss.15-22, 2009 (SCI-Expanded)
Aliskiren is a novel molecule which blocks the renin-angiotensin-aldosterone system in its rate limiting step by renin inhibition. Aliskiren is validated as an antihypertensive drug in many countries based on its efficacy data. Although some surrogate endpoint trials suggest that its potential advantages based on its mechanism of action provide clinical benefit beyond its blood pressure-lowering effect, hard endpoint clinical trials to reveal its long-term effects are yet to be completed.